Was verursacht Multiple Sklerose?

2010 ◽  
Vol 29 (12) ◽  
pp. 820-824
Author(s):  
M. Paulig
Keyword(s):  
Vitamin D ◽  
Life Events ◽  
Multiple Sklerose ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Genetische Suszeptibilität ◽  
Epstein Barr

ZusammenfassungDie Ätiologie der Multiplen Sklerose (MS) ist unbekannt. Obwohl oft vermutet scheint eine monokausale Pathogenese unwahrscheinlich. Gegenwärtig wird die Entstehung der MS als multifaktorieller Prozess gesehen, in dem verschiedene Risikofaktoren wirksam sind, die sowohl eine genetische Suszeptibilität als auch Umwelteinflüsse beinhalten. Verschiedene Risikoallele wurden mittlerweile identifiziert. Unter den Umweltfaktoren gelten aktuell eine geringe Sonnenexposition, niedrige Vitamin-D-Spiegel und eine durchgemachte Infektion mit Epstein-Barr-Virus als Hauptkandidaten für ein erhöhtes Risiko MS zu entwickeln. Darüber hinaus stehen noch Ernährungsgewohnheiten, Rauchen, Hormone und Life Events unter Verdacht, eine Rolle bei MS zu spielen. Allerdings ist keiner dieser Faktoren eine notwendige oder hinlängliche Bedingung für MS. Genauere Kenntnisse der Kausalkette, die zu MS führt, werden wahrscheinlich neue Strategien für die Therapie und Prävention ermöglichen.

Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein–Barr virus in relapsing-remitting multiple sclerosis

2016 ◽  
Vol 23 (3) ◽  
pp. 395-402 ◽  
Author(s):  
Egil Røsjø ◽  
Andreas Lossius ◽  
Nada Abdelmagid ◽  
Jonas C Lindstrøm ◽  
Margitta T Kampman ◽  
...  
Keyword(s):  
Vitamin D ◽  
Epstein Barr Virus ◽  
High Dose ◽  
Oral Vitamin ◽  
Barr Virus ◽  
Relapsing Remitting ◽  
Dose Oral ◽  
Epstein Barr ◽  
Antibody Levels ◽  
Relapsing Remitting Multiple Sclerosis

Background: Elevated antibody levels against Epstein–Barr virus (EBV) and a poor vitamin D status are environmental factors that may interact in relapsing-remitting multiple sclerosis (RRMS) aetiology. Objectives: To examine effects of high-dose oral vitamin D3 supplementation on antibody levels against EBV nuclear antigen 1 (EBNA1) in RRMS. Methods: Serum 25-hydroxyvitamin D3 (25(OH)D) and immunoglobulin G antibody levels against EBNA1 (whole protein and amino acid 385–420 fragment), EBV viral capsid antigen (VCA), cytomegalovirus (CMV) and varicella zoster virus (VZV) were measured in 68 RRMS patients enrolled in a 96-week randomised double-blinded placebo-controlled clinical trial of oral vitamin D3 supplementation (20,000 IU/week) (NCT00785473). Results: The mean 25(OH)D level more than doubled in the vitamin D group and was significantly higher than in the placebo group at study conclusion (123.2 versus 61.8 nmol/L, p < 0.001). Compared to the placebo group, both anti-EBNA1 protein and fragment antibody levels decreased in the vitamin D group from baseline to week 48 ( p = 0.038 and p = 0.004, respectively), but not from baseline to week 96. Vitamin D3 supplementation did not affect antibodies against VCA, CMV or VZV. Conclusion: The results indicate that high-dose oral vitamin D3 supplementation can affect humoral immune responses against the latent EBV antigen EBNA1 in RRMS.

scholarly journals Solar Ultraviolet Radiation and Vitamin D Deficiency on Epstein-Barr Virus Reactivation: Observational and Genetic Evidence From a Nasopharyngeal Carcinoma-Endemic Population

2020 ◽  
Vol 7 (10) ◽  
Author(s):  
Zhi-Ming Mai ◽  
Jia-Huang Lin ◽  
Roger Kai-Cheong Ngan ◽  
Dora Lai-Wan Kwong ◽  
Wai-Tong Ng ◽  
...  
Keyword(s):  
Vitamin D ◽  
Ultraviolet Radiation ◽  
Epstein Barr Virus ◽  
Virus Reactivation ◽  
Solar Ultraviolet Radiation ◽  
Logistic Regression Models ◽  
Hydroxyvitamin D ◽  
Barr Virus ◽  
Epstein Barr ◽  
Using Data

Abstract Background We investigated the relationship of Epstein-Barr virus viral capsid antigen (EBV VCA-IgA) serostatus with ambient and personal ultraviolet radiation (UVR) and vitamin D exposure. Methods Using data from a multicenter case-control study, we included 1026 controls subjects in 2014–2017 in Hong Kong, China. Odds ratios (ORs) and 95% confidence intervals (CIs) of the association between UVR exposure and EBV VCA-IgA (seropositivity vs seronegativity) were calculated using unconditional logistic regression models adjusted for potential confounders. Results We observed a large increase in seropositivity of EBV VCA-IgA in association with duration of sunlight exposures at both 10 years before recruitment and age 19–30 years (adjusted OR = 3.59, 95% CI = 1.46–8.77; and adjusted OR = 2.44, 95% CI = 1.04–5.73 for ≥8 vs &lt;2 hours/day; P for trend = .005 and .048, respectively). However, no association of EBV VCA-IgA serostatus with other indicators of UVR exposure was found. In addition, both circulating 25-hydroxyvitamin D (25OHD) and genetic predicted 25OHD were not associated with EBV VCA-IgA serostatus. Conclusions Our results suggest that personal UVR exposure may be associated with higher risk of EBV reactivation, but we did not find clear evidence of vitamin D exposure (observational or genetic), a molecular mediator of UVR exposure. Further prospective studies in other populations are needed to confirm this finding and to explore the underlying biological mechanisms. Information on photosensitizing agents, and serological markers of EBV, and biomarkers related to systemic immunity and inflammation should be collected and are also highly relevant in future studies.

scholarly journals Treatment of Infectious Mononucleosis with High Dose Vitamin D3 in Three Cases

2021 ◽  
Vol 8 (1) ◽  
Author(s):  
Schwalfenberg GK ◽  
Keyword(s):  
Vitamin D ◽  
Vitamin D Receptor ◽  
Infectious Mononucleosis ◽  
Epstein Barr Virus ◽  
Fungal Infections ◽  
High Dose ◽  
Significant Morbidity ◽  
Barr Virus ◽  
Epstein Barr ◽  
High Dose Vitamin

Infectious mononucleosis often results in significant morbidity and disability lasting up to six months. It is known that vitamin D induces cathelicidin production that can rapidly responds to some viral, bacterial and fungal infections. The Epstein Barr virus is able to block the vitamin D receptor thus blocking the ability to fight this infection. This article presents three cases, which responded quickly to loading doses of vitamin D (150,000-200,000 IU) followed by a month of 10,000IU daily.

Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients

2016 ◽  
Vol 23 (6) ◽  
pp. 1064-1070 ◽  
Author(s):  
S. Wergeland ◽  
K.-M. Myhr ◽  
K. I. Løken-Amsrud ◽  
A. G. Beiske ◽  
K. S. Bjerve ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Prospective Cohort ◽  
Epstein Barr Virus ◽  
Virus Antibody ◽  
Barr Virus ◽  
Epstein Barr ◽  
Multiple Sclerosis Patients ◽  
Antibody Levels

Multiple sclerosis-associated retrovirus, Epstein-Barr virus, and vitamin D status in patients with relapsing remitting multiple sclerosis

2017 ◽  
Vol 89 (7) ◽  
pp. 1309-1313 ◽  
Author(s):  
Aliehossadat Mostafa ◽  
Somayeh Jalilvand ◽  
Zabihollah Shoja ◽  
Ahmad Nejati ◽  
Shohreh Shahmahmoodi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Epstein Barr Virus ◽  
Vitamin D Status ◽  
Barr Virus ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Epstein Barr ◽  
Relapsing Remitting Multiple Sclerosis

scholarly journals Response to Vitamin D Supplementation during Antarctic Winter Is Related to BMI, and Supplementation Can Mitigate Epstein-Barr Virus Reactivation

2011 ◽  
Vol 141 (4) ◽  
pp. 692-697 ◽  
Author(s):  
Sara R. Zwart ◽  
Satish K. Mehta ◽  
Robert Ploutz-Snyder ◽  
YaVonne Bourbeau ◽  
James P. Locke ◽  
...  
Keyword(s):  
Vitamin D ◽  
Epstein Barr Virus ◽  
Vitamin D Supplementation ◽  
Virus Reactivation ◽  
Barr Virus ◽  
Epstein Barr ◽  
Epstein Barr Virus Reactivation
Sign in / Sign up

Export Citation Format

Share Document